Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001720157 | SCV000522754 | likely benign | not provided | 2020-11-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001720157 | SCV000556285 | likely benign | not provided | 2023-12-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000567088 | SCV000671496 | likely benign | Hereditary cancer-predisposing syndrome | 2016-01-22 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Department of Pathology and Laboratory Medicine, |
RCV001354167 | SCV001548711 | likely benign | Carcinoma of colon | no assertion criteria provided | clinical testing | The POLE p.Ser1827= variant was not identified in the literature nor was it identified in the Cosmic database. The variant was identified in dbSNP (ID: rs775867327) as "With Likely benign allele ", and in ClinVar (classified as likely benign by GeneDx, Invitae, Ambry Genetics). The variant was identified in control databases in 2 of 246210 chromosomes at a frequency of 0.000008 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 1 of 15302 chromosomes (freq: 0.000065), European in 1 of 111684 chromosomes (freq: 0.000009), but was not observed in the Other, Latino, Ashkenazi Jewish, East Asian, Finnish, and South Asian populations. The p.Ser1827= variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. In addition, in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. |